Alacris Theranostics GmbH
ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015
Alacris Theranostics GmbH / Key word(s): Miscellaneous/Miscellaneous Press Release ______________________________________________________________ ALACRIS RECEIVES GERMAN INNOVATION AWARD 2015 Berlin, 28th April 2015 – Alacris Theranostics GmbH announced today that they have been awarded the highly renowned German Innovation Award 2015. Alacris Theranostics received the award in the category Medium-Sized Enterprises for ModCellTM, an innovative system biology-based modelling approach for personalised diagnostics, therapy and drug stratification with an initial focus on cancer. ModCellTM can predict potential effects and side effects of treatments on the basis of a detailed molecular analysis of the patient’s tumor to support physicians in their decision making for an optimized therapy for each individual patient (currently in a clinical trial). In addition, ModCellTM can be used in both, biomarker identification and for the development and repositioning of drugs. By simulating drug activity in “virtual clinical trials”, ModCellTM allows for a faster, more efficient drug development and approval process. The unique feature of ModCellTM is the use of a systems biology model in the field of personalised medicine which is significantly different from statistical, correlative approaches, in most cases based only on single or multiple biomarkers. The analysis of individual biomarkers allows only examination of a partial aspect of the disease. ModCellTM however, generates a computer model of a “virtual patient” on the basis of analysing the totality of the biological data and therefore helps to identify individualised, promising treatment strategies for cancer patients. “We are delighted that the jury of the German Innovation Award has honoured our innovative ModCellTM modelling approach,” commented Bodo Lange, PhD, CEO of Alacris Theranostics GmbH. “The award is an important recognition of our approach and our work. This prize further encourages us to continuously develop and improve ModCellTM for achieving the best possible treatment for patients in the fight against cancer.” Alacris has established its own state-of-the-art Next Generation Sequencing Laboratory in Berlin with the appropriate sequencing and data analysis capabilities in order to generate data for the modelling of patients and tumours. With the development and commercialisation of this innovation in personalised healthcare, Alacris also attracts highly qualified international young scientists to the Berlin area. Berlin plays an important role as an attractive location for researchers, companies, founders and consequently investors. About German Innovation Award About Alacris Theranostics GmbH
Alacris Theranostics GmbH MC Services AG 2015-04-28 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
349739 2015-04-28 |